Abstract: A computer system accesses a multiplatform firmware image to obtain a GUID identifying a platform for the computer system. The multiplatform firmware image includes a core firmware volume and a plurality of platform-specific firmware volumes. The computer system installs a platform identifier interface including the GUID. The computer system executes files within a platform-specific firmware volume including the GUID and a file of the core firmware volume including the GUID based at least in part on dependency expressions of the executed files and the platform identifier interface.

Abstract: A non-transitory computer-readable storage medium storing a multiplatform image which can be used to boot a computer implementing one of a plurality of platforms includes a core firmware volume and one or more platform-specific firmware volumes. The core firmware volume includes common files used by each of the plurality of platforms and at least one file that may be used by some the plurality of platforms but not the others of the plurality of platforms. The one or more platform-specific firmware volumes includes files that are different in at least two of the platforms.

Abstract: The invention provides a method of treating inflammation, comprising administering to a subject in need thereof a therapeutically effective amount of an agent that inhibits binding of fibrin to Very Low Density Lipoprotein Receptor (VLDLR) or combination of this agent with agents inhibiting binding of fibrin to VE-cahherin (vascular endothelial cadherin).

Abstract: A composition including a peptide sequence of the formula ?X1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type ?15-42 monomer sequence per se, and wherein the peptide sequence is other than (?15-66)2 dimer having two chains with each chain limited to wild type amino acids ?15-65 and each chain further including a non-naturally occurring Gly at position 66 of each chain. Methods for treatment and pharmaceutical combinations may include a polypeptide agent such as Thymosin beta 4.

Abstract: A composition including a peptide sequence of the formula ?X1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type ?15-42 monomer sequence per se, and wherein the peptide sequence is other than (?15-66)2 dimer having two chains with each chain limited to wild type amino acids ?15-65 and each chain further including a non-naturally occurring Gly at position 66 of each chain. Methods for treatment and pharmaceutical combinations may include a polypeptide agent such as Thymosin beta 4.